Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 GBX | 0.00% | +3.57% | +70.59% |
04-26 | Auckett Swanke shares down as half-year loss widens | AN |
04-26 | AIM WINNERS & LOSERS: Proteome Sciences rises on GBP500,000 contract | AN |
Valuation
Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 3.684 | 2.437 | 2.643 | 3.304 | 3.965 | 5.025 |
Enterprise Value (EV) 1 | 3.527 | 1.385 | 4.731 | 5.793 | 6.505 | 9.148 |
P/E ratio | -1.57 x | 7.04 x | 533 x | -2.9 x | -1.73 x | 44.5 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.28 x | 0.18 x | 0.23 x | 0.37 x | 0.56 x | 0.36 x |
EV / Revenue | 0.27 x | 0.1 x | 0.42 x | 0.66 x | 0.91 x | 0.65 x |
EV / EBITDA | -1.4 x | 28.3 x | -17.2 x | -4.97 x | -36.3 x | 163 x |
EV / FCF | 4.69 x | 2.43 x | -24.5 x | -10.2 x | 9.39 x | -4.52 x |
FCF Yield | 21.3% | 41.2% | -4.09% | -9.77% | 10.6% | -22.1% |
Price to Book | 0.88 x | 0.56 x | 0.61 x | 1.08 x | 9.89 x | 1.49 x |
Nbr of stocks (in thousands) | 165,214 | 165,214 | 165,214 | 165,214 | 165,214 | 275,356 |
Reference price 2 | 0.0223 | 0.0148 | 0.0160 | 0.0200 | 0.0240 | 0.0182 |
Announcement Date | 31/01/19 | 30/01/20 | 19/04/21 | 31/03/22 | 28/03/23 | 28/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 13.09 | 13.71 | 11.34 | 8.822 | 7.127 | 14.1 |
EBITDA 1 | -2.515 | 0.049 | -0.275 | -1.166 | -0.179 | 0.056 |
EBIT 1 | -2.756 | -0.182 | -0.428 | -1.354 | -0.304 | -0.067 |
Operating Margin | -21.05% | -1.33% | -3.78% | -15.35% | -4.27% | -0.48% |
Earnings before Tax (EBT) 1 | -2.544 | 0.292 | -0.046 | -1.531 | -1.824 | -0.351 |
Net income 1 | -2.345 | 0.346 | 0.005 | -1.123 | -2.282 | 0.092 |
Net margin | -17.91% | 2.52% | 0.04% | -12.73% | -32.02% | 0.65% |
EPS 2 | -0.0142 | 0.002094 | 0.000030 | -0.006899 | -0.0138 | 0.000410 |
Free Cash Flow 1 | 0.752 | 0.57 | -0.1935 | -0.566 | 0.6926 | -2.024 |
FCF margin | 5.74% | 4.16% | -1.71% | -6.42% | 9.72% | -14.35% |
FCF Conversion (EBITDA) | - | 1,163.27% | - | - | - | - |
FCF Conversion (Net income) | - | 164.74% | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 31/01/19 | 30/01/20 | 19/04/21 | 31/03/22 | 28/03/23 | 28/03/24 |
Balance Sheet Analysis
Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | 2.09 | 2.49 | 2.54 | 4.12 |
Net Cash position 1 | 0.16 | 1.05 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | -7.593 x | -2.135 x | -14.19 x | 73.62 x |
Free Cash Flow 1 | 0.75 | 0.57 | -0.19 | -0.57 | 0.69 | -2.02 |
ROE (net income / shareholders' equity) | -42.7% | 7.68% | -0.45% | -30.5% | -103% | 4.35% |
ROA (Net income/ Total Assets) | -13.9% | -0.99% | -2.18% | -6.84% | -1.89% | -0.36% |
Assets 1 | 16.85 | -34.87 | -0.2291 | 16.43 | 120.7 | -25.37 |
Book Value Per Share 2 | 0.0300 | 0.0300 | 0.0300 | 0.0200 | 0 | 0.0100 |
Cash Flow per Share 2 | 0 | 0.0100 | 0.0100 | 0 | 0 | 0 |
Capex 1 | 0.08 | 0.09 | 0.25 | 0.03 | 0.05 | 0.15 |
Capex / Sales | 0.6% | 0.66% | 2.16% | 0.37% | 0.67% | 1.09% |
Announcement Date | 31/01/19 | 30/01/20 | 19/04/21 | 31/03/22 | 28/03/23 | 28/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+70.59% | 5.33M | |
-11.92% | 3.96B | |
+49.15% | 2.29B | |
+18.64% | 1.95B | |
+26.63% | 1.75B | |
-15.60% | 1.51B | |
+14.84% | 1.16B | |
+14.05% | 986M | |
+40.87% | 933M | |
+28.95% | 905M |
- Stock Market
- Equities
- AUK Stock
- Financials Aukett Swanke Group Plc